Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Representation of a bacteriophage docking on a target molecule in a bacterial membrane. The harnessing of bacteriophage antimicrobial strategies to identify novel bactericidal mechanisms allows the design of assays to screen small molecule libraries for compounds mimicking those effects (see Liu et al., p 185). Electron microscopy images of Staphylococcus aureus phage 77, courtesy of Dr. Hans-Wolfgang Ackermann, Department of Medical Biology, Laval University, Quebec, Canada. Artwork by InViVo Communications Inc. Toronto, Canada.
Immunomodulator CTLA4-Ig was set to be the miracle drug for organ transplantation a dozen years ago, but then faded from view. Now, with startling results in rheumatoid arthritis, costimulatory blockers are on a comeback. Ken Garber reports.
Permissive regulations in a few regions of the world are dictating where human embryonic stem (hES) cell research is taking place, but this could change as numerous countries are still formulating policy.
A novel approach for identifying synergistic mixtures of skin penetration enhancers promises to transform development of transdermal products, including patches.
Rather than using bacteriophage themselves as treatments, a new approach recruits them in the search for antibiotics with new antibacterial mechanisms.
A survey reveals that the way in which genetic sequences are claimed in granted patents are heterogeneous and imprecise, which may lead to questions regarding their validity.